Lv41
690 积分 2023-11-13 加入
分子肿瘤专家委员会（MTB）临床实践中国专家共识
15天前
已完结
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
3个月前
已完结
Reversing “Flip-Flop” Phenomenon of 131I and Glucose Avidity in RET-Fusion Positive Radioiodine-Refractory Thyroid Cancer Lesions After Treatment of Pralsetinib
3个月前
已完结
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
8个月前
已完结
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
8个月前
已完结
EP.12B.09 Real-World Efficacy and Toxicity Comparison Between the RET Inhibitors (RETi) Pralsetinib and Selpercatinib in Patients with Stage IV NSCLC
9个月前
已完结
Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
11个月前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
11个月前
已完结
皖公网安备34019202002308
